Teva Pharmaceutical Industries Ltd Adr (TEVA)

Nov 02, 2025

Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November - Sahm

Nov 02, 2025

Nov 02, 2025

Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05 - GlobeNewswire Inc.

Nov 02, 2025

Nov 01, 2025

Earnings call transcript: Teva’s Q2 2025 shows steady growth, stock rises - Investing.com

Nov 01, 2025

Oct 29, 2025

Teva Pharmaceutical Industries Ltd (TEVA) Stock Price, Trades & News - GuruFocus

Oct 29, 2025

Oct 28, 2025

eBay Upgraded, Meta Platforms Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Oct 28, 2025

Oct 26, 2025

ETFs Investing in Teva Pharmaceutical Industries Limited Sponsored ADR Stocks - TradingView

Oct 26, 2025

Oct 25, 2025

TEVA Stock Price and Chart — VIE:TEVA - TradingView

Oct 25, 2025

Oct 20, 2025

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe - Sahm

Oct 20, 2025

Oct 15, 2025

SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures - Sahm

Oct 15, 2025

Oct 10, 2025

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder - Sahm

Oct 10, 2025

Oct 09, 2025

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs - Sahm

Oct 09, 2025

Oct 07, 2025

SciSparc And AutoMax Call Off Merger - Sahm

Oct 07, 2025

Oct 06, 2025

AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Oct 06, 2025

Sep 21, 2025

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction - Ariva

Sep 21, 2025

Sep 20, 2025

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed - Ariva

Sep 20, 2025

Sep 16, 2025

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting - Sahm

Sep 16, 2025

Sep 14, 2025

Bayforest Capital Ltd Sells 3,875 Shares of Teva Pharmaceutical Industries Ltd. $TEVA - Defense World

Sep 14, 2025

Sep 09, 2025

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy - Ariva

Sep 09, 2025

Sep 09, 2025

Teva Pharmaceutical ADR Trying To Close In On Key Technical Measure - inkl

Sep 09, 2025

Aug 29, 2025

Teva stock rises on launch of first generic weight loss GLP-1 drug - Investing.com Nigeria

Aug 29, 2025

Aug 28, 2025

Teva Shares Rise Following Launch of First Generic GLP-1 Weight Loss Drug - MSN

Aug 28, 2025

Aug 28, 2025

Teva stock rises on launch of first generic weight loss GLP-1 drug By Investing.com - Investing.com South Africa

Aug 28, 2025

Aug 28, 2025

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss - Placera.se

Aug 28, 2025

Aug 21, 2025

TEVA Stock Price and Chart — TASE:TEVA - TradingView

Aug 21, 2025

Aug 18, 2025

Earnings call transcript: Teva’s Q2 2025 earnings beat fails to lift revenue - Investing.com

Aug 18, 2025

Aug 13, 2025

Teva (TEVA) Is Up 5.7% After FDA Approves AJOVY for Pediatric Migraine Prevention - Sahm

Aug 13, 2025

Aug 12, 2025

Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Stock: Navigating a Year of Volatility - investchronicle.com

Aug 12, 2025

Aug 06, 2025

Teva's AJOVY Receives FDA Approval for Pediatric Migraine Treatment - AInvest

Aug 06, 2025

Aug 06, 2025

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine - Ariva

Aug 06, 2025

Aug 04, 2025

TEVA’s Stock Market Puzzle: Piecing Together 2025’s Performance - investchronicle.com

Aug 04, 2025

Jul 30, 2025

Teva's Pivot to Growth Strategy Underway as Innovative Portfolio Impresses and Pipeline Looks Solid - Morningstar

Jul 30, 2025

Jul 30, 2025

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components - Ariva

Jul 30, 2025

Jul 22, 2025

Head-To-Head Contrast: Teva Pharmaceutical Industries (NYSE:TEVA) & Taysha Gene Therapies (NASDAQ:TSHA) - Defense World

Jul 22, 2025

Jul 16, 2025

Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Drops -2.31%, Turning Investors Away - Stocksregister

Jul 16, 2025

Jun 26, 2025

The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?26.06.25News - Ariva

Jun 26, 2025

Jun 20, 2025

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Bought by Yousif Capital Management LLC - Defense World

Jun 20, 2025

Jun 17, 2025

Can Teva- Pharmaceutical Industries Ltd. ADR Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com

Jun 17, 2025

Jun 09, 2025

Stocks Generating Improved Relative Strength: Teva Pharmaceutical ADR - MSN

Jun 09, 2025

May 29, 2025

Teva: New Long-Term Targets and Sold Pipeline Reaffirm Our Favorable Outlook; Shares Undervalued - Morningstar

May 29, 2025

May 29, 2025

Teva: New Long-Term Targets and Solid Pipeline Reaffirm Our Favorable Outlook; Shares Undervalued - Morningstar

May 29, 2025